GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Klotho Neurosciences Inc (NAS:KLTO) » Definitions » Capital Expenditure

KLTO (Klotho Neurosciences) Capital Expenditure : $-0.12 Mil (TTM As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Klotho Neurosciences Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Klotho Neurosciences's cash flow for capital expenditures for the three months ended in Dec. 2024 was $0.00 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Dec. 2024 was $-0.12 Mil.

Klotho Neurosciences Capital Expenditure Historical Data

The historical data trend for Klotho Neurosciences's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Klotho Neurosciences Capital Expenditure Chart

Klotho Neurosciences Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Capital Expenditure
- -0.13 -0.01 -0.12

Klotho Neurosciences Quarterly Data
Dec21 Jun22 Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Capital Expenditure Get a 7-Day Free Trial Premium Member Only Premium Member Only - -0.12 - - -

Klotho Neurosciences Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.12 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Klotho Neurosciences Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Klotho Neurosciences Inc (NAS:KLTO) » Definitions » Capital Expenditure
Comparable Companies
AIMI CERO BZYR AZTR CELZ CPMV KTTA SILO IBO CMND VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
N/A
Address
13576 Walnut Street, Suite A, Omaha, NE, USA, 68144
Website
https://www.klothoneuro.com
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.